Back to Agenda
Session 4A: Global Landscape of Falsified Medicines and Global Landscape of Serialization
Session Chair(s)
Terrance Ocheltree, PhD, RPh
VP, Head of Regulatory Affairs and Quality Assurance
Corium, Inc., United States
To combat the increasing risk of falsified medicines in the global market many countries have or plan to initiate serialization and traceability requirements. The lack of coordination of these efforts has the potential to create conflicting requirements and complex operational challenges for all stakeholders in the pharmaceutical supply chain. This session will highlight the current challenges facing the pharmaceutical industry to track and trace global medicinal products, discuss harmonized approaches pertaining to serialization, and provide a regulator’s perspective to addressing falsified medicines. During the panel discussion, you will have the opportunity to ask questions and share ideas on approaches to secure pharmaceutical products supply chains to ensure that patients receive safe and effective medicinal products.
Speaker(s)
Supply Chain Integrity: FDA Perspective on Falsified Medicines and Serialization
Eleni Anagnostiadis, RPh
FDA, United States
Director, PASES, OCD, CDER
Global Development in Serialization and the Need for Harmonization
Eric M. Marshall, JD
Leavitt Partners, United States
Senior Director
DSCSA - Drug Supply Chain Security Act
Lloyd Mager
AbbVie, United States
Global Traceability Lead
Have an account?